UCHealth Blood Disorders and Cell Therapies Center - Anschutz Medical Campus1665 Aurora Court 3rd floor, Anschutz Cancer Pavilion, Aurora, CO 80045
UCH - Anschutz Inpatient Pavilion12605 E. 16th Ave Aurora, CO 80045
Clinical Interest for Patients
Multiple myeloma and other plasma cell disorders
Not all myeloma cancers are the same; therefore tailoring the treatment to the patient is key to successful outcomes.
- Internal Medicine ( 2005 , 2015 )
- Hematology ( 2008 , 2018 )
- Medical Oncology ( 2008 , 2018 )
Conditions & Treatments
Amyloid, Blood and Marrow Transplant, Myeloma
Dr. Mark earned a Bachelor of Science degree from Yale University, where he majored in Molecular Biochemistry and Biophysics. He received his Doctorate in Medicine with distinction in research from the State University of New York at Stony Brook. He then completed his residency in Internal Medicine at Beth Israel Deaconess Medical Center in Boston. Dr. Mark completed fellowship in Hematology and Medical Oncology in 2008 at Weill Cornell Medical College in New York City. He also received a Master of Science degree in Clinical Investigation from the Weill Cornell School of Graduate Sciences and completed the American Society of Hematology Clinical Research Training Institute during his fellowship training. After fellowship, Dr. Mark stayed on at Cornell and became associate director of the Multiple Myeloma Center and later director of the inpatient myeloma service at the New York Presbyterian Hospital, Cornell campus. In 2016, he joined the University of Colorado as clinical director of the plasma cell disorders program, which will cover conditions such as multiple myeloma, AL amyloidosis, light chain deposition disease, POEMS syndrome and other rare malignancies related to abnormal plasma cell function. Dr. Mark?s research focus has been on development of novel therapies for the care of multiple myeloma, including stem cell collection protocols and transplantation conditioning regimens. He is currently a member of the International Myeloma Working Group and co-chair of the plasma cell disease committee at the Center for International Blood and Marrow Transplant Research. He has been principal investigator on multiple early to late phase clinical trials as well as the author of several book chapters on the subject of plasma cell disorders. While clinical research is a major focus for Dr. Mark, his work also centers on providing the best patient experience possible. He has worked with patient advocacy groups as well alongside his patients to help improve care. He has also coauthored a book with one of his patients: ?Love, Olivia: A Stem Cell Transplant Story.?
MD, The School of Medicine at Stony Brook University Medical Center (2002)
BS, Yale University (CT) (1998)
Beth Israel Deaconess Medical Center/Harvard Medical School Program
Beth Israel Deaconess Medical Center/Harvard Medical School Program (2005)
New York Presbyterian Hospital (Cornell Campus) Program (2008)
International Myeloma Society, member
International Myeloma Working Group, member
Research Interests for Patients
Dr. Mark?s research focus has been on development of novel therapies for the care of multiple myeloma, including stem cell collection protocols and transplantation conditioning regimens. As a clinical trialist, he has been principal investigator on phase 1 trials of new compounds for use in refractory myeloma and stem cell transplantation. He has also led phase 2 and 3 studies designed to maximize treatment efficacy in newly diagnosed and relapsed myeloma. As every myeloma is genetically distinct, his aim to develop and deliver personalized therapy for every patient based on scientific rationale.